Brief: US FDA Approves Talazoparib With Enzalutamide For Metastatic HRR-Mutated Prostate Cancer
26/10/2026 17:28
BRIEF-US FDA Approves Talazoparib With Enzalutamide For Metastatic HRR-Mutated Prostate Cancer Oct 26 (Reuters) - US FDA:
US FDA: APPROVES TALAZOPARIB WITH ENZALUTAMIDE FOR METASTATIC HRR-MUTATED PROSTATE CANCER
Further company coverage: PFE.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pfizer
See all newsBrief: Enanta Pharmaceuticals In Patent Infringement Action Against Pfizer
Brief: Edison Scientific Announces Agreement With Pfizer To Accelerate Research And Development
Bristol Myers raises 2026 revenue forecast, lowers EPS due to charge (updated)
Corrected: Bristol Myers raises 2026 revenue forecast, lowers EPS due to charge
Brief: Pfizer’S ELREXFIO Outperforms Standard Regimens And Meets Primary Endpoint In Phase 3 Study In Relapsed Or Refractory Multiple Myeloma